Abstract
Introduction
Panic disorder (PD) affects a large number of people and has a large diagnosed
and drug-treated population. Nonetheless, the pipeline for agents to treat PD
remains small, eclipsed by the development of agents for other anxiety
disorders. This dearth opens a clear opportunity for an emerging agent that
can offer superior effi cacy over the available options.
Get the Answers You Need to Shape Your Strategy
- PD can be highly debilitating, with the associated anxiety causing those
with this d ? isease to signifi cantly limit their activities. How many
people in the seven major markets we cover (the United States, France,
Germany, Italy, Spain, the United Kingdom, and Japan) have PD? What brain
structures and neurotransmitters have been implicated in the development of
PD? How is the disease diagnosed?
- A variety of drug classes are used to treat PD. What are the most
popular therapies for the treatment of PD? Does approval for the treatment of
the disease increase the likelihood it will be prescribed?
- Few agents are being developed for the treatment of PD. Why are drug
developers choosing to develop agents for anxiety orders other than PD? What
agents are currently in the pipeline for PD, and are they likely to replace
any existing agents? What changes can be expected in the PD market over the
next five years?
Scope
- Overview of PD: disease description, diagnosis, pathophysiology,
and prevalence.
- Current therapies: selective serotonin reuptake inhibitors,
serotonin and norepinephrine reuptake inhibitors, and benzodiazepines.
- Emerging therapies: challenges to developing agents for PD,
Sepracor' s SEP-225441, and Alexza Pharmaceuticals' AZ-002.
- PD market: 2007 statistics, outlook for emerging agents.
| 
View Cart
